Developer docs
API playgroundTry for free, no card

Search company profiles

Amphix Bio

Full company profile

uuid0002ir4

Namestring
Amphix Bio
Legal namestring
Amphix Bio, Inc.
Websiteurl
amphixbio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Amphix Bio is a preclinical-stage biotechnology company developing regenerative medicine therapies using its proprietary Supramolecular Therapeutic Peptide (STP) platform. Founded in 2021 as a spinout from Northwestern University and headquartered in Chicago, the company applies supramolecular chemistry to design peptide amphiphile molecules that self-assemble into dynamic 3D nanostructure scaffolds mimicking the natural extracellular environment, thereby activating regenerative signaling pathways in cells. The company's pipeline is led by AMFX-200, a neuroregenerative candidate for acute spinal cord injury and other neurological conditions (chronic SCI, ischemic stroke, ALS, Parkinson's disease, neuropathy), and AMFX-100, an off-the-shelf bone graft substitute for spinal fusion surgery to treat degenerative disc disease. The platform is grounded in 20+ years of research from Prof. Samuel Stupp's laboratory, supported by 100+ peer-reviewed publications and 30+ issued patents, and has been validated across 50+ animal studies and 100+ screened molecules.

AMFX-200 has received FDA Orphan Drug Designation for acute spinal cord injury, while AMFX-100 has received FDA Breakthrough Device Designation for bone regeneration, both providing exclusivity incentives and expedited development pathways. Preclinical data include unprecedented motor function recovery in spinal cord injury models and a 100-fold reduction in required recombinant BMP-2 dose versus current clinical bone graft products.

Amphix Bio is currently pre-revenue with no commercial products and 1–10 employees. Its forward business model will rely on pharmaceutical/medical device distribution channels and direct engagement with orthopedic surgeons and hospital procurement for AMFX-100, and specialty neurology channels for AMFX-200 upon regulatory approval, or alternatively on out-licensing or partnership transactions. To date the company has raised $18 million in total funding, including NSF SBIR Phase I and Phase II grants ($1M Phase II in October 2024) and a $12.5 million seed financing completed in December 2025, with proceeds directed toward IND-enabling studies, manufacturing scale-up, and pipeline expansion.

Short descriptiontext

Amphix Bio is a preclinical-stage Northwestern University spinout developing supramolecular therapeutic peptide therapies for neurological and musculoskeletal conditions, including AMFX-200 for spinal cord injury and AMFX-100 for spinal fusion bone grafting.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, peptide therapeutics, spinal cord injury, bone regeneration, tissue engineering
Industry3 codes
PRIMARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Regenerative Medicine Therapeutics
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Amphix Bio develops regenerative medicine therapies built on a Supramolecular Therapeutic Peptide (STP) platform. Its lead candidate AMFX-200 is a neuroregenerative therapeutic targeting acute spinal cord injury and other neurological conditions (chronic SCI, ischemic stroke, ALS, Parkinson's, neuropathy) by combining peptide drugs with a nanofiber scaffold. Its second lead candidate AMFX-100 is an off-the-shelf bone graft substitute for spinal fusion in degenerative disc disease, eliminating the need for donor tissue or recombinant proteins. Both candidates are in preclinical development advancing toward human clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100-fold dose reduction in recombinant BMP-2 compared to current clinical products for bone regeneration
+3 more records
Product overview1 text field

Amphix Bio is developing a peptide therapeutic platform based on Supramolecular Therapeutic Peptides (STP). The company's portfolio includes two lead product candidates: AMFX-200, a neuroregenerative treatment for acute spinal cord injury and other neurological conditions that combines peptide drugs with nanofiber scaffolds, and AMFX-100, an off-the-shelf bone graft substitute for spinal fusion surgery to treat degenerative disc disease. Both products are built on the company's STP Platform, which uses supramolecular chemistry to create nanostructures that activate cell receptors and promote tissue regeneration. The platform has been validated through extensive preclinical studies including over 50 animal studies across therapeutic areas.

Product and service2 records
1AMFX-200
CategoryRegenerative Medicine Therapeutics
Description

Lead neuroregenerative therapeutic candidate combining peptide drug pharmacological action with a nanofiber scaffold to promote neural regeneration. Preclinical data shows unprecedented motor function recovery, reduction in neuropathic pain and inflammatory responses, and prevention of glial scar formation in spinal cord injury models. Being developed for acute spinal cord injury, chronic spinal cord injury, ischemic stroke, ALS, Parkinson's disease, and neuropathy. Granted FDA Orphan Drug Designation.

2AMFX-100
CategoryBone Regeneration Therapeutic
Description

Off-the-shelf synthetic bone graft substitute designed to enable spinal fusion in degenerative disc disease without donor tissue or recombinant proteins. Preclinical studies show induction of new bone tissue formation with a 100-fold dose reduction in recombinant BMP-2 compared to current clinical products. Granted FDA Breakthrough Device Designation.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology originated from Prof. Samuel Stupp's laboratory at Northwestern University with 20+ years of research; company co-founded by Northwestern researchers; ongoing collaboration with CRN for preclinical studies including spinal cord injury models and rehabilitation studies; Charlotte Chen's PhD research from Stupp Lab incorporated into bone regeneration therapy

2Christopher & Dana Reeve Foundation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-sponsored research grant with Spinal Research to test AMFX-200 in combination with structured physical rehabilitation in acute and chronic spinal cord injury models; aligned mission to support patients and families living with spinal cord injury

amphixbio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-sponsored research grant with Christopher & Dana Reeve Foundation to test AMFX-200 in combination with structured physical rehabilitation in preclinical spinal cord injury models

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing NVG-291, a peptide therapeutic targeting nervous system repair, with a primary indication in acute spinal cord injury. NervGen is the most directly comparable company to AMFX-200, pursuing a peptide-based neuroregenerative mechanism for the same SCI patient population.

TypeDirect peer
Description

Clinical-stage cell therapy company advancing OPC1 (oligodendrocyte progenitor cells) for acute spinal cord injury, the same indication as AMFX-200. Lineage is a direct competitor in SCI regeneration and provides a benchmark for clinical timelines and regulatory pathways in this indication.

TypeDirect peer
Description

Commercial-stage orthobiologics company whose i-FACTOR bone graft is a peptide-enhanced bone matrix used in cervical spine fusion. Cerapedics is the most directly comparable commercial-stage company to AMFX-100, using a small peptide to drive bone regeneration in spinal fusion.

TypeDirect peer
Description

Late-stage regenerative medicine company developing cellular therapies for inflammatory and degenerative conditions across multiple indications. Mesoblast shares Amphix Bio's strategy of leveraging a single platform across diverse high-unmet-need diseases, including orthopedic and inflammatory applications.

TypeBroad incumbent
Description

Global medical device leader and the incumbent in the US spinal fusion market via its INFUSE Bone Graft / recombinant human BMP-2 product. Medtronic is the dominant competitor AMFX-100 must displace on cost, safety, and dose-efficiency grounds.

TypeBroad incumbent
Description

Major diversified orthopedic medical device company with a broad spine and biologics portfolio including bone graft substitutes and synthetic scaffolds. Stryker represents the broad incumbent competitive set that AMFX-100 will face in hospital formulary and orthopedic surgeon adoption.

TypeBroad incumbent
Description

Large spine-focused medical device company (post-NuVasive merger) offering an extensive portfolio of spinal fusion implants, biologics, and enabling technologies. Globus is a key customer-channel incumbent and potential strategic acquirer/partner for Amphix Bio's bone regeneration product.

TypeBroad incumbent
Description

Spine and orthopedic device company with a biologics segment including bone graft substitutes for spinal fusion. Orthofix competes directly with AMFX-100 in the regenerative spine market and represents another potential commercial partnership or acquisition target.

9Athersys
TypeEmerging player
Description

Clinical-stage regenerative medicine company developing MultiStem cell therapy for neurological, inflammatory, and cardiovascular indications. Athersys shares Amphix Bio's multi-indication platform thesis and serves as a relevant comparable for capital-efficient regenerative medicine development.

TypeBroad incumbent
Description

Specialty neurology company historically focused on spinal cord injury and multiple sclerosis, including dalfampridine for improved walking in MS patients. Acorda represents a strategic acquirer/partner profile with deep SCI commercial expertise and is a relevant comparable for SCI market dynamics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amphix Bio

Regenerative Medicine Therapeuticsamphixbio.com

Amphix Bio is a preclinical-stage Northwestern University spinout developing supramolecular therapeutic peptide therapies for neurological and musculoskeletal conditions, including AMFX-200 for spinal cord injury and AMFX-100 for spinal fusion bone grafting.

What Amphix Bio does

Amphix Bio is a preclinical-stage biotechnology company developing regenerative medicine therapies using its proprietary Supramolecular Therapeutic Peptide (STP) platform. Founded in 2021 as a spinout from Northwestern University and headquartered in Chicago, the company applies supramolecular chemistry to design peptide amphiphile molecules that self-assemble into dynamic 3D nanostructure scaffolds mimicking the natural extracellular environment, thereby activating regenerative signaling pathways in cells. The company's pipeline is led by AMFX-200, a neuroregenerative candidate for acute spinal cord injury and other neurological conditions (chronic SCI, ischemic stroke, ALS, Parkinson's disease, neuropathy), and AMFX-100, an off-the-shelf bone graft substitute for spinal fusion surgery to treat degenerative disc disease. The platform is grounded in 20+ years of research from Prof. Samuel Stupp's laboratory, supported by 100+ peer-reviewed publications and 30+ issued patents, and has been validated across 50+ animal studies and 100+ screened molecules.

AMFX-200 has received FDA Orphan Drug Designation for acute spinal cord injury, while AMFX-100 has received FDA Breakthrough Device Designation for bone regeneration, both providing exclusivity incentives and expedited development pathways. Preclinical data include unprecedented motor function recovery in spinal cord injury models and a 100-fold reduction in required recombinant BMP-2 dose versus current clinical bone graft products.

Amphix Bio is currently pre-revenue with no commercial products and 1–10 employees. Its forward business model will rely on pharmaceutical/medical device distribution channels and direct engagement with orthopedic surgeons and hospital procurement for AMFX-100, and specialty neurology channels for AMFX-200 upon regulatory approval, or alternatively on out-licensing or partnership transactions. To date the company has raised $18 million in total funding, including NSF SBIR Phase I and Phase II grants ($1M Phase II in October 2024) and a $12.5 million seed financing completed in December 2025, with proceeds directed toward IND-enabling studies, manufacturing scale-up, and pipeline expansion.

Amphix Bio firmographics

Firmographics
Name
Amphix Bio
Legal name
Amphix Bio, Inc.
Website
https://amphixbio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Amphix Bio is a preclinical-stage Northwestern University spinout developing supramolecular therapeutic peptide therapies for neurological and musculoskeletal conditions, including AMFX-200 for spinal cord injury and AMFX-100 for spinal fusion bone grafting.
Ownership category
akta.pro rank

Amphix Bio industry classification

Industry
Product category
Regenerative Medicine Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative medicine
  • Peptide therapeutics
  • Spinal cord injury
  • Bone regeneration
  • Tissue engineering

Where Amphix Bio is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Amphix Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Distribution channels1 record

Marketing channels4 records

Amphix Bio product offering

Product offering

Core offering

Amphix Bio develops regenerative medicine therapies built on a Supramolecular Therapeutic Peptide (STP) platform. Its lead candidate AMFX-200 is a neuroregenerative therapeutic targeting acute spinal cord injury and other neurological conditions (chronic SCI, ischemic stroke, ALS, Parkinson's, neuropathy) by combining peptide drugs with a nanofiber scaffold. Its second lead candidate AMFX-100 is an off-the-shelf bone graft substitute for spinal fusion in degenerative disc disease, eliminating the need for donor tissue or recombinant proteins. Both candidates are in preclinical development advancing toward human clinical trials.

Product overview

Amphix Bio is developing a peptide therapeutic platform based on Supramolecular Therapeutic Peptides (STP). The company's portfolio includes two lead product candidates: AMFX-200, a neuroregenerative treatment for acute spinal cord injury and other neurological conditions that combines peptide drugs with nanofiber scaffolds, and AMFX-100, an off-the-shelf bone graft substitute for spinal fusion surgery to treat degenerative disc disease. Both products are built on the company's STP Platform, which uses supramolecular chemistry to create nanostructures that activate cell receptors and promote tissue regeneration. The platform has been validated through extensive preclinical studies including over 50 animal studies across therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • AMFX-200 Lead neuroregenerative therapeutic candidate combining peptide drug pharmacological action with a nanofiber scaffold to promote neural regeneration. Preclinical data shows unprecedented motor function recovery, reduction in neuropathic pain and inflammatory responses, and prevention of glial scar formation in spinal cord injury models. Being developed for acute spinal cord injury, chronic spinal cord injury, ischemic stroke, ALS, Parkinson's disease, and neuropathy. Granted FDA Orphan Drug Designation.
  • AMFX-100 Off-the-shelf synthetic bone graft substitute designed to enable spinal fusion in degenerative disc disease without donor tissue or recombinant proteins. Preclinical studies show induction of new bone tissue formation with a 100-fold dose reduction in recombinant BMP-2 compared to current clinical products. Granted FDA Breakthrough Device Designation.

Quantifiable outcome

  • 100-fold dose reduction in recombinant BMP-2 compared to current clinical products for bone regeneration
  • +3 more outcomes

Companies that use Amphix Bio

Customer profile

Segments3 records

Ideal customer profiles2 records

Amphix Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Amphix Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Northwestern University - Center for Regenerative Nanomedicine (CRN)coreStrategic or Co-development PartnerTechnology originated from Prof. Samuel Stupp's laboratory at Northwestern University with 20+ years of research; company co-founded by Northwestern researchers; ongoing collaboration with CRN for preclinical studies including spinal cord injury models and rehabilitation studies; Charlotte Chen's PhD research from Stupp Lab incorporated into bone regeneration therapy
  • Christopher & Dana Reeve FoundationcoreStrategic or Co-development PartnerCo-sponsored research grant with Spinal Research to test AMFX-200 in combination with structured physical rehabilitation in acute and chronic spinal cord injury models; aligned mission to support patients and families living with spinal cord injury
  • Spinal ResearchcoreStrategic or Co-development PartnerCo-sponsored research grant with Christopher & Dana Reeve Foundation to test AMFX-200 in combination with structured physical rehabilitation in preclinical spinal cord injury models

Scale indicators15 records

Recent moves7 records

Expansion highlights5 records

Amphix Bio competitors and assessment

Company assessment

Direct peers

  • NervGen Pharma: Clinical-stage biotech developing NVG-291, a peptide therapeutic targeting nervous system repair, with a primary indication in acute spinal cord injury. NervGen is the most directly comparable company to AMFX-200, pursuing a peptide-based neuroregenerative mechanism for the same SCI patient population.
  • Lineage Cell Therapeutics: Clinical-stage cell therapy company advancing OPC1 (oligodendrocyte progenitor cells) for acute spinal cord injury, the same indication as AMFX-200. Lineage is a direct competitor in SCI regeneration and provides a benchmark for clinical timelines and regulatory pathways in this indication.
  • Cerapedics: Commercial-stage orthobiologics company whose i-FACTOR bone graft is a peptide-enhanced bone matrix used in cervical spine fusion. Cerapedics is the most directly comparable commercial-stage company to AMFX-100, using a small peptide to drive bone regeneration in spinal fusion.
  • Mesoblast: Late-stage regenerative medicine company developing cellular therapies for inflammatory and degenerative conditions across multiple indications. Mesoblast shares Amphix Bio's strategy of leveraging a single platform across diverse high-unmet-need diseases, including orthopedic and inflammatory applications.

Broad incumbents

  • Medtronic: Global medical device leader and the incumbent in the US spinal fusion market via its INFUSE Bone Graft / recombinant human BMP-2 product. Medtronic is the dominant competitor AMFX-100 must displace on cost, safety, and dose-efficiency grounds.
  • Stryker: Major diversified orthopedic medical device company with a broad spine and biologics portfolio including bone graft substitutes and synthetic scaffolds. Stryker represents the broad incumbent competitive set that AMFX-100 will face in hospital formulary and orthopedic surgeon adoption.
  • Globus Medical: Large spine-focused medical device company (post-NuVasive merger) offering an extensive portfolio of spinal fusion implants, biologics, and enabling technologies. Globus is a key customer-channel incumbent and potential strategic acquirer/partner for Amphix Bio's bone regeneration product.
  • Orthofix: Spine and orthopedic device company with a biologics segment including bone graft substitutes for spinal fusion. Orthofix competes directly with AMFX-100 in the regenerative spine market and represents another potential commercial partnership or acquisition target.
  • Acorda Therapeutics: Specialty neurology company historically focused on spinal cord injury and multiple sclerosis, including dalfampridine for improved walking in MS patients. Acorda represents a strategic acquirer/partner profile with deep SCI commercial expertise and is a relevant comparable for SCI market dynamics.

Emerging players

  • Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy for neurological, inflammatory, and cardiovascular indications. Athersys shares Amphix Bio's multi-indication platform thesis and serves as a relevant comparable for capital-efficient regenerative medicine development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Amphix Bio social profiles

Digital presence

Amphix Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amphix Bio leadership team

Management profile

Number of profiles

Profiles11 records

Amphix Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amphix Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amphix Bio

What does Amphix Bio do?

Amphix Bio develops regenerative medicine therapies built on a Supramolecular Therapeutic Peptide (STP) platform. Its lead candidate AMFX-200 is a neuroregenerative therapeutic targeting acute spinal cord injury and other neurological conditions (chronic SCI, ischemic stroke, ALS, Parkinson's, neuropathy) by combining peptide drugs with a nanofiber scaffold. Its second lead candidate AMFX-100 is an off-the-shelf bone graft substitute for spinal fusion in degenerative disc disease, eliminating the need for donor tissue or recombinant proteins. Both candidates are in preclinical development advancing toward human clinical trials.

Is Amphix Bio a public or private company?

Amphix Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Amphix Bio founded?

Amphix Bio was founded in 2021. It employs 1 to 10 people.

Where is Amphix Bio based?

Amphix Bio is headquartered in Chicago, United States, in the North America region.

Who are Amphix Bio's main competitors?

Direct peers on record are NervGen Pharma, Lineage Cell Therapeutics, Cerapedics and Mesoblast. Broad incumbents are Medtronic, Stryker, Globus Medical, Orthofix and Acorda Therapeutics. Athersys is listed as an emerging player.

Does Amphix Bio have an API?

No public API is recorded for Amphix Bio.

What industry is Amphix Bio in?

Amphix Bio's product category is Regenerative Medicine Therapeutics. Its primary akta.pro industry code is HLAAAGAI, Neural & Spinal Cord Regeneration, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireThe Reeve Foundation and Spinal Research Award New Grants to Advance Traumatic Spinal Cord Injury TreatmentsThe Christopher & Dana Reeve Foundation and Spinal Research have announced $1.5 million in grants to support four preclinical studies focused on developing new treatments for traumatic spinal cord injury. The grants, awarded to research institutions and biotechnology companies, aim to bridge the critical funding gap between early scientific discoveries and the advanced studies required before regulatory review for human clinical trials. Recipients include Novoron Bioscience, Amphix Bio, and researchers from the University of Toronto and University of Washington, each pursuing different therapeutic approaches such as drug candidates, stem cell therapies, and repurposed FDA-approved treatments.ChristopherreeveThe Reeve Foundation and Spinal Research Award New Grants to Advance Traumatic Spinal Cord Injury TreatmentsThe Christopher & Dana Reeve Foundation and Spinal Research have announced $1.5 million in grants to support four preclinical studies focused on developing new treatments for traumatic spinal cord injury, with each project receiving $250,000 over two years. The grants aim to bridge the critical funding gap between early scientific discoveries and the advanced studies required for regulatory approval for human clinical trials. Recipients include Novoroo Bioscience (studying NOVO-120 for bladder dysfunction), University of Toronto (advancing stem cell therapy), Amphix Bio (researching NUPA-200 gel combined with rehabilitation), and University of Washington (repurposing an FDA-approved enzyme therapy).BioSpaceAmphix Bio raises $12.5M seed round to advance peptide drug platformAmphix Bio announced the initial closing of a $12.5 million seed financing round to advance its Supramolecular Therapeutic Peptide (STP) platform toward human clinical trials, with the funding also supporting pipeline expansion into additional neurological conditions including stroke, Parkinson's disease, and ALS. The company has achieved recent regulatory milestones including Orphan Drug Designation for its lead candidate AMFX-200 and Breakthrough Device Designation for its drug-device combination product AMFX-100, bringing its total funding to $18 million. The platform, developed over two decades of research at Northwestern University, uses assemblies of thousands of molecules forming nanostructures engineered to activate cell receptors more potently than standard drugs.Pulse 2.0Amphix Bio: $12.5 Million Seed Funding Raised To Advance Peptide Therapeutics Toward Clinical TrialsAmphix Bio, a Chicago-based biotech company, completed an initial closing of a $12.5 million seed financing round to advance its supramolecular peptide therapeutics toward human clinical trials, bringing total dilutive and non-dilutive funding to $18 million. The company received Orphan Drug Designation for its lead neurological candidate AMFX-200 for acute spinal cord injury and Breakthrough Device Designation for AMFX-100, a drug-device combination for degenerative disc disease, while completing a Type C meeting with the FDA. The platform technology, licensed from Northwestern University where co-founder Samuel Stupp served as chief scientific officer, targets neurological injuries, neurodegenerative diseases, and musculoskeletal disorders through modified peptide assemblies.PR NewswireAmphix Bio raises $12.5M seed round to advance peptide drug platformAmphix Bio announced the initial closing of a $12.5 million seed financing round to develop its peptide drug platform, targeting neurological and musculoskeletal conditions, and to advance its lead candidates towards clinical trials. The company received regulatory designations for two of its products, including Orphan Drug and Breakthrough Device Designations from the FDA. The funding aims to expand indications and develop the platform for broader therapeutic use.VentureRadarNew Funding Rounds in advanced polymersThe article lists multiple venture funding rounds for companies in the advanced polymers and biotech sectors, including Amphix Bio raising $12.5M, ProLynx securing $70 million, and Xeltis obtaining $55.1 million. These investments support various initiatives ranging from peptide drug platforms to biodegradable materials and 3D printing technologies. The content serves as a market update on recent capital raises within this specific industry segment.VC News DailyAmphix Bio Announces $12.5M Seed RoundAmphix Bio announced the initial closing of a $12.5 million seed financing round to advance its lead therapeutic candidates toward human clinical trials and expand its pipeline targeting additional neurological conditions. The funding, from mission-driven investors, brings the company's total dilutive and non-dilutive funds raised to $18 million. The Chicago-based biotech company, which spun out from Northwestern University in 2021, is developing Supramolecular Therapeutic Peptides platform technology aimed at restoring function lost from injury, disease, or aging.SecSEC FORM DAmphix Bio, Inc., a Delaware-incorporated biotechnology company headquartered in Chicago, Illinois, filed a SEC Form D notice on December 18, 2025 for an exempt equity offering under Rule 506(b). The filing reports a total offering amount of $12.5 million, with $10.3 million already sold to 9 investors and $2.2 million remaining, with first sales occurring on December 4, 2025. The company, founded over five years ago, disclosed revenue as undisclosed and identified five executive officers and directors including CEO Nicholas Sather.Northwestern's McCormick School of Engineering‘Dancing Molecules’ Treatment Receives FDA Orphan Drug DesignationThe FDA granted orphan drug designation to 'Dancing Molecules,' a spinal cord injury therapy developed by Samuel Stupp at Northwestern University. The treatment, which gels into nanofibers to support axon regrowth, has received early FDA feedback, with Amphix Bio targeting late 2026 for first human trials.PR NewswireAmphix Bio receives FDA Orphan Drug Designation for neural regeneration therapeutic to treat acute spinal cord injuryAmphix Bio received FDA Orphan Drug Designation for its lead candidate AMFX-200 to treat acute spinal cord injury. The STP-based therapy has shown in preclinical models that a single injection can restore motor function after injury. The company is now completing safety studies to begin a first-in-human clinical trial.